183 related articles for article (PubMed ID: 32241437)
1. Leishmania lipophosphoglycan components: A potent target for synthetic neoglycoproteins as a vaccine candidate for leishmaniasis.
Mohammed ASA; Tian W; Zhang Y; Peng P; Wang F; Li T
Carbohydr Polym; 2020 Jun; 237():116120. PubMed ID: 32241437
[TBL] [Abstract][Full Text] [Related]
2. Leishmania lipophosphoglycan: how to establish structure-activity relationships for this highly complex and multifunctional glycoconjugate?
Forestier CL; Gao Q; Boons GJ
Front Cell Infect Microbiol; 2014; 4():193. PubMed ID: 25653924
[TBL] [Abstract][Full Text] [Related]
3. Conjugation, characterization and toxicity of lipophosphoglycan-polyacrylic acid conjugate for vaccination against leishmaniasis.
Topuzogullari M; Cakir Koc R; Dincer Isoglu S; Bagirova M; Akdeste Z; Elcicek S; Oztel ON; Yesilkir Baydar S; Canim Ates S; Allahverdiyev AM
J Biomed Sci; 2013 Jun; 20(1):35. PubMed ID: 23731716
[TBL] [Abstract][Full Text] [Related]
4. Synthetic neoglycoconjugates of cell-surface phosphoglycans of Leishmania as potential anti-parasite carbohydrate vaccines.
Nikolaev AV; Sizova OV
Biochemistry (Mosc); 2011 Jul; 76(7):761-73. PubMed ID: 21999537
[TBL] [Abstract][Full Text] [Related]
5. Leishmaniasis in humans: drug or vaccine therapy?
Ghorbani M; Farhoudi R
Drug Des Devel Ther; 2018; 12():25-40. PubMed ID: 29317800
[TBL] [Abstract][Full Text] [Related]
6. New insights to structure and immunological features of Leishmania lipophosphoglycan3.
Hosseini M; Haji-Fatahaliha M; Miahipour A; Yousefi M
Biomed Pharmacother; 2017 Nov; 95():1369-1374. PubMed ID: 28946184
[TBL] [Abstract][Full Text] [Related]
7. Solution and solid-support synthesis of a potential leishmaniasis carbohydrate vaccine.
Hewitt MC; Seeberger PH
J Org Chem; 2001 Jun; 66(12):4233-43. PubMed ID: 11397159
[TBL] [Abstract][Full Text] [Related]
8. An efficient and stereoselective synthesis of beta-D-Arap-(1-->2)-beta-D-Galp-(1-->3)-beta-D-Galp-(1-->4)-alpha-D-Manp, a tetrasaccharide fragment of Leishmania major lipophosphoglycan.
Yashunsky DV; Higson AP; Ross AJ; Nikolaev AV
Carbohydr Res; 2001 Dec; 336(4):243-8. PubMed ID: 11728392
[TBL] [Abstract][Full Text] [Related]
9. Parasite glycoconjugates. Part 16: Synthesis of a disaccharide and phosphorylated di- and tri-saccharides from Leishmania lipophosphoglycan.
Ross AJ; Sizova OV; Nikolaev AV
Carbohydr Res; 2006 Aug; 341(11):1954-64. PubMed ID: 16697981
[TBL] [Abstract][Full Text] [Related]
10. Surface determinants of Leishmania parasites and their role in infectivity in the mammalian host.
Naderer T; Vince JE; McConville MJ
Curr Mol Med; 2004 Sep; 4(6):649-65. PubMed ID: 15357214
[TBL] [Abstract][Full Text] [Related]
11. Lipophosphoglycan of the protozoan parasite Leishmania: stage- and species-specific importance for colonization of the sandfly vector, transmission and virulence to mammals.
Ilg T
Med Microbiol Immunol; 2001 Nov; 190(1-2):13-7. PubMed ID: 11770101
[TBL] [Abstract][Full Text] [Related]
12. The preparation of neoglycoconjugates containing inter-saccharide phosphodiester linkages as potential anti-Leishmania vaccines.
Routier FH; Nikolaev AV; Ferguson MA
Glycoconj J; 1999 Dec; 16(12):773-80. PubMed ID: 11133017
[TBL] [Abstract][Full Text] [Related]
13. Vaccines for leishmaniasis: from proteome to vaccine candidates.
Schroeder J; Aebischer T
Hum Vaccin; 2011; 7 Suppl():10-5. PubMed ID: 21245661
[TBL] [Abstract][Full Text] [Related]
14. Structure of Leishmania lipophosphoglycan: inter- and intra-specific polymorphism in Old World species.
McConville MJ; Schnur LF; Jaffe C; Schneider P
Biochem J; 1995 Sep; 310 ( Pt 3)(Pt 3):807-18. PubMed ID: 7575413
[TBL] [Abstract][Full Text] [Related]
15. Parasite escape mechanisms: the role of Leishmania lipophosphoglycan on the human phagocyte functions. A review.
Panaro MA; Panunzio M; Jirillo E; Marangi A; Brandonisio O
Immunopharmacol Immunotoxicol; 1995 Aug; 17(3):595-605. PubMed ID: 8576549
[TBL] [Abstract][Full Text] [Related]
16. Developmentally regulated changes in the cell surface architecture of Leishmania parasites.
McConville MJ; Ralton JE
Behring Inst Mitt; 1997 Mar; (99):34-43. PubMed ID: 9303200
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of the immunogenicity of synthetic carbohydrates by conjugation to virosomes: a leishmaniasis vaccine candidate.
Liu X; Siegrist S; Amacker M; Zurbriggen R; Pluschke G; Seeberger PH
ACS Chem Biol; 2006 Apr; 1(3):161-4. PubMed ID: 17163663
[TBL] [Abstract][Full Text] [Related]
18. Transmission blocking vaccine studies in leishmaniasis: I. Lipophosphoglycan is a promising transmission blocking vaccine molecule against cutaneous leishmaniasis.
Tonui WK; Mbati PA; Anjili CO; Orago AS; Turco SJ; Githure JI; Koech DK
East Afr Med J; 2001 Feb; 78(2):84-9. PubMed ID: 11682952
[TBL] [Abstract][Full Text] [Related]
19. An α-Gal-containing neoglycoprotein-based vaccine partially protects against murine cutaneous leishmaniasis caused by Leishmania major.
Iniguez E; Schocker NS; Subramaniam K; Portillo S; Montoya AL; Al-Salem WS; Torres CL; Rodriguez F; Moreira OC; Acosta-Serrano A; Michael K; Almeida IC; Maldonado RA
PLoS Negl Trop Dis; 2017 Oct; 11(10):e0006039. PubMed ID: 29069089
[TBL] [Abstract][Full Text] [Related]
20. How to master the host immune system? Leishmania parasites have the solutions!
Rossi M; Fasel N
Int Immunol; 2018 Mar; 30(3):103-111. PubMed ID: 29294040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
